Alphatec Holdings, Inc. · NASDAQ:ATEC
Alphatec — Q3 2026 Earnings Presentation
16 slides from Alphatec's earnings presentation, Oct 29, 2026
Slide 1: Q3 2026 Financial Results
Q3 2026 FINANCIAL RESULTS PAT MILES, CHAIRMAN & CEO | TODD KONING, EVP & CFO | OCTOBER 29, 2026
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation and the accompanying conference call contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such statements are based on management's current expectations and a
Slide 3: Industry-Leading Profitable Growth: Q3 2026 Highlights
INDUSTRY- $221M Total Revenue LEADING PROFITABLE GROWTH 14% Surgical Revenue 20% Case Volume 25% Net-New Surgeon Growth Growth Growth Q3 2026 HIGHLIGHTS $20M EOS Revenue $38M Adjusted EBITDA $6M Free Cash Generated 3 | Reference non-GAAP reconciliation in appendix
Slide 4: Q3 Revenue Performance
Q3 REVENUE PERFORMANCE STRONG REVENUE GROWTH DRIVEN BY SURGICAL VOLUME Q3 2 02 6 YOY$ YOY% $25M Surgical Revenue Surgical Revenue $202M $25M 14% YoY $ Growth EOS Revenue $20M - (1%) • 25% growth in surgeon users TOTAL REVENUE $221M $25M 13% • 20% surgical volume growth, driven by strong adoption of
Slide 5: Q3 2026 Non-GAAP P&L Highlights
Q3 2026 NON-GAAP P&L HIGHLIGHTS MEANINGFUL OPERATING LEVERAGE DESPITE SOFTER TOPLINE AEBITDA $M AEBITDA % Q3 2 02 6 YOY $40 40% $35 35% TOTAL REVENUE $221M 13% $30 30% $25 25% Gross Margin % 71.9% 180 bps $20 20% R&D % 6.9% (90 bps) $15 15% $10 10% SG&A % 55.2% (160 bps) $5 5% Total Operating Expens
Slide 6: Q3 Balance Sheet
Q3 BALANCE SHEET STRONG CASH GENERATION SUPPORTS CONTINUED INVESTMENT AND FINANCIAL FLEXIBILITY BA L A NC E S HE E T Q3 2 02 6 C A S H F L OW Q3 2 02 6 Cash $80M Operating Cash Flow2 $34M Available Borrowing1 $55M Inventory and PP&E ($29M) CASH + AVAILABLE CASH $135M FREE CASH FLOW3 $6M Fifth cons
Slide 7: 2026 Revenue Outlook
2026 REVENUE OUTLOOK STRONG SURGICAL DEMAND DRIVES 15% GROWTH $862M +$102M FY’26E YOY Total Revenue Surgical Revenue $789M 15% YoY Surgical Revenue EOS Revenue $73M (5%) SURGICAL DRIVERS: TOTAL REVENUE $862M 13% • High-teens Case Volume Growth • LSD Rev per Case Decline 7
Slide 8: 2026 Financial Outlook
2026 FINANCIAL OUTLOOK MAINTAINING STRONG ADJUSTED EBITDA DESPITE LOWER REVENUE OUTLOOK DOUBLE-DIGIT GROWTH SIGNIFICANT LEVERAGE FREE CASH FLOW $862M Total revenue; $ 137M Adjusted EBITDA; $10M Investing in growth and 13% growth 16% margin | 47% growth generating cash EXPANDING PROFITABILITY + CASH
Slide 9: Our Strategy Remains Steadfast
OUR STRATEGY REMAINS STEADFAST DELIVERING ON THE FUNDAMENTALS OF OUR LONG-TERM GROWTH ALGORITHM 1 2 3 CREATE CLINICAL COMPEL SURGEON EXPAND, ELEVATE & DISTINCTION ADOPTION ENABLE SALES FORCE Architect unparalleled Earn loyalty through Build a high-performing, procedural solutions differentiated trai
Slide 10: Clinical Distinction Earns Trust and Compounds Adoption
CLINICAL DISTINCTION EARNS TRUST AND COMPOUNDS ADOPTION PCF ACDF CONFIDENCE IN ONE PROCEDURE EXPANDS INTO MORE OF THE SURGEON’S PRACTICE POSTERIOR FIXATION PLIF LTP PTP TLIF ALIF 10
Slide 11: EOS Creates Strategic Access, Influencing the Next Generation of Spine Surgeons
EOS CREATES STRATEGIC ACCESS, INFLUENCING THE NEXT GENERATION OF SPINE SURGEONS >70% MARKET SHARE ACROSS ACADEMIC INSTITUTIONS 11
Slide 12: EOS Insight Turns Data Into Advantage
EOS INSIGHT TURNS DATA INTO ADVANTAGE TRANSFORMING A GROWING DATASET INTO ACTIONABLE CLINICAL INTELLIGENCE 12
Slide 13: Becoming Indispensable in the O.R.
BECOMING INDISPENSABLE IN THE O.R. INTEGRATING INTELLIGENCE INTO THE PROCEDURE AT A FRACTION OF THE PHYSICAL FOOTPRINT 13
Slide 14: 2026 Financial Outlook
2026 FINANCIAL OUTLOOK MAINTAINING STRONG ADJUSTED EBITDA DESPITE LOWER REVENUE OUTLOOK DOUBLE-DIGIT GROWTH SIGNIFICANT LEVERAGE FREE CASH FLOW $862M Total revenue; $ 137M Adjusted EBITDA; $10M Investing in growth and 13% growth 16% margin | 47% growth generating cash EXPANDING PROFITABILITY + CASH
Slide 15: The Preferred Destination in Spine
THE PREFERRED DESTINATION IN SPINE.
Slide 16: Appendix
APPENDIX 16